ArticleNPJ cardiovascular health2025
Distinct endothelial cells in chronic thromboembolic pulmonary hypertension.
Article in NPJ cardiovascular health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition characterized by unresolved thrombi obstructing the pulmonary arteries. Endothelial cells (ECs) are essential regulators of thrombosis and thrombus resolution, yet their molecular phenotypes in CTEPH are incompletely understood. Using single-cell RNA sequencing of CTEPH surgical specimens and control ECs from the Human Lung Cell Atlas, we uncover marked EC heterogeneity in CTEPH. Compared to controls, CTEPH ECs display marked phenotypic shifts, with the loss and emergence of distinct EC subpopulations, including a unique subset co-expressing pulmonary and bronchial EC markers. Our analysis reveals perturbed endothelial thrombosis regulation, encompassing coagulation, fibrinolysis, inflammation, TGF-β signaling, and angiogenesis, while identifying novel target genes. These findings provide a comprehensive view of endothelial contributions to delayed thrombus resolution, offering new insights into the pathophysiology of CTEPH and potential therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.